# Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso

> **NCT01017770** · PHASE4 · COMPLETED · sponsor: **Centre Muraz** · enrollment: 340 (estimated)

## Conditions studied

- Uncomplicated P. Falciparum Malaria in Children

## Interventions

- **DRUG:** Artesunate-amodiaquine
- **DRUG:** Artemether-lumefantrine

## Key facts

- **NCT ID:** NCT01017770
- **Lead sponsor:** Centre Muraz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-08
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2015-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017770, "Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01017770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*